











recruitment Elaine M Boyle, SurfON Chief Investigator COMET Conference 26 September 2025



A multicentre, pragmatic, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress



Research question

In babies born at 34^{+0} - 38^{+6} weeks of gestation with respiratory distress, where the clinical plan is to give non-invasive respiratory support

does

I the early use of surfactant

compared with

C expectant management

result in

o shorter hospital stay and reduced incidence of severe respiratory disease



Study criteria

Inclusion criteria

- 1. Born at 34⁺⁰–38⁺⁶ weeks of gestation
- 2. ≤ 24 hours old
- 3. Respiratory distress, defined as:
 - FiO₂ \geq 0.3 and < 0.45 to maintain oxygen saturations SaO₂ \geq 92%

or

- FiO₂ with clinically significant work of breathing
- 4. Clinical decision to provide noninvasive respiratory support
- 5. Written parental informed consent

Exclusion criteria

- 1. Major structural or chromosomal abnormality
- 2. No realistic prospect of survival
- 3. Prior intubation and/or surfactant administration
- 4. Known or suspected hypoxic ischaemic encephalopathy
- 5. Congenital abnormality of the respiratory tract
- 6. Known or suspected neuromuscular disorder



Study Objectives

- To compare, in infants randomised to receive early surfactant versus those who received expectant management
 - duration of neonatal hospital stay
 - incidence of severe respiratory failure
 - perinatal secondary outcomes
 - cost-effectiveness
- A pragmatic study



Primary outcomes

- Length of infant's hospital stay after birth, defined as the number of days from birth to discharge home from hospital
- 2. Incidence of severe respiratory failure, defined as sustained (\geq 30 minutes) requirement for FiO₂ \geq 0.45 to maintain SaO₂ \geq 92%



Current clinical practice


- Variable between and within neonatal units
- Some clinicians treat early with surfactant to prevent deterioration
- Some prefer to adopt a 'watch and wait' approach
- No defined limits for intervention
- No evidence for either approach
- Both can be regarded as "standard care"
- No RCTs in this group of babies





SurfON prior to recruitment pause – Feb 2022

Target, actual & projected recruitment, projected for 6 months





What happened during the pause?

- Site visits by the CI and SurfON team
- Prepared 11 new sites to open
- Registered for the NIHR Associate PI scheme
- Introduced SurfON Champion scheme
- Negotiated for ANNPs to be able to confirm eligibility
- Regular site communications and updates in newsletters and emails
- Increased engagement via CRN East Midlands
- Raised awareness of SurfON at national and international conferences
- Publication: "optimising the management of respiratory distress in late preterm and early term babies", Infant journal
- Gained understanding recruitment challenges, questions around trial equipoise and exchanged tips and suggestions




Top tips for success

- Have as many people as possible on the delegation log
- Approach parents as early as possible
- Appoint Study Champions
- Use regular reminders and resources
- Discuss the study at unit meetings
- Review the eligible babies that are not recruited
- Bite-size online drop-in training sessions
- Example video for recruitment
- Recorded debate about the study





Ongoing recruitment







Lack of staff

Research question no longer relevant

Poor understanding of importance

Trial fatigue

Lack of support from CI or CTU

Recruitment

Lack of training


Lack of incentive

Lack of time


Loss of equipoise

Trial too complex






















What to focus on?





Ongoing relevance

Surfactant use in late preterm infants: a survey among Belgian neonatologists. Cornette L, Mulder A, Debeer A, et al. Eur J Pediatr. 2021 Mar;180(3):885-892. doi: 10.1007/s00431-020-03806-1. Epub 2020 Sep 24.PMID: 32970243

Our survey demonstrates a significant variability in practice between neonatologists during treatment of respiratory pathologies in LPT infants. This highlights an urgent need for univocal therapeutic lines.

Surfactant therapy in late preterm and term neonates with respiratory distress syndrome: a systematic review and meta-analysis. Ramaswamy VV, Abiramalatha T, Bandyopadhyay T, Boyle E, Roehr CC. Arch Dis Child Fetal Neonatal Ed. 2022 Jul;107(4):393-397. doi: 10.1136/archdischild-2021-322890. Epub 2021 Oct 22.PMID: 34686533

In view of the low to very low CoE and widely varying thresholds for deciding on surfactant replacement in the included studies, further trials are needed.

Management of respiratory distress syndrome in moderate/late preterm neonates: A Delphi consensus. Rite Gracia S, Agüera Arenas JJ, Ginovart Galiana G, Rodríguez Revuelta MJ. An Pediatr (Engl Ed). 2024 Nov 1:S2341-2879(24)00262-X. doi: 10.1016/j.anpede.2024.10.003.

Most panellists agreed on the need for studies that determine the benefit/harm balance, clinical profile and methods of surfactant administration in moderate/late preterm neonates.

Finally, all respondents agreed that there is a lack of studies identifying risk factors and medium-term adverse outcomes in moderate/late preterm neonates.



Clinical equipoise

- Underpins all randomised controlled trials
- Uncertainty or disagreement exists among clinicians about the relative merits of different treatment options in a given condition/situation
- Different clinicians may prefer different approaches for the same patient
- There is no evidence that one approach is better than the other
- Trials are designed so that, if successfully conducted, the results should be convincing enough to resolve disagreement




Important points to remember

- Research aims to improve outcomes for a given population by providing the highest quality evidence to inform care
- Studies are carefully and thoughtfully designed with appropriate inclusion and exclusion criteria to maximise the benefit for all
- Deviation from these because of personal prejudice or paternalism will lead to biased results
- It is our job to make parents aware of research for which their baby is eligible and whether or not to allow their baby to take part in research for which they are eligible must be their decision not ours



Ongoing recruitment







Slow increase in sites and recruitment



Steady increase in sites and recruitment

Increase in sites but slowing in recruitment

1515 of target 1522 recruited by end of April 2025





My belief:

It is the *right of every family* to be given the opportunity to participate in available research that may benefit their baby or future babies

In the absence of robust evidence, we should not be making paternalistic judgements about who should and should not be approached based on our personal opinions.



Thank you!

Project Management Group

Vasha Bari

Diya Bhandari

Christina Cole

Pollyanna Hardy

Andy King

Ramon Luengo-Fernandez

David Murray

Heather O'Connor

Oliver Rivero Arias

Charles Roehr

Pauline Rushby

Zainab Aslam

Kayleigh Stanbury

Richard Welsh

Louise Linsell

Pip Crowley

National Institute for Health and Care Research



Previous Trial Managers

Indrani Manoharan Linda Mottram

Sarah Turner

Clinical Investigators Group

Ben Stenson

David Sweet

Marie Hubbard

Oliver Rivero Arias

Ed Juszczak

Bliss

Data Monitoring Committee

Mark Johnson Alison Leaf Lee Middleton

Trial Steering Committee

William McGuire

Catherine Hewitt

Paul Fleming

Simon Dixon

Peter Reynolds

Pollyanna Hardy

Heather Tinkler (Parent rep)

Melissa Ashford (Parent Rep)

Parents and Babies

All local Principal Investigators

Research staff and clinical staff at all

participating sites

Family, friends and colleagues





